These radionuclides can either be injected as a simple formulation such as [223Ra]RaCl2 (Xofigo®) for palliative treatment of prostate cancer bone metastases 3, or radiolabeled onto targeting vectors to create radiopharmaceuticals, such as [68Ga]Ga-PSMA-11 for diagnosing prostate-specific membrane antigen (PSMA) expressing prostate cancer 4. This evidence concerns the gene FOLH1 and prostate cancer.